Evidence-based (S3) guideline for the treatment of psoriasis vulgaris-Update: "therapeutic options" and "efalizumab": Guideline;S3-Leitlinie zur Therapie der Psoriasis vulgaris-Update: "übersicht der Therapieoptionen" und "efalizumab"

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 1, 2010, Pages 65-66

  Nast, Alexander ^l   Augustin, Matthias ^a   Boehncke, Wolf Henning ^b   Klaus, Joachim ^c   Mrowietz, Ulrich ^d   Ockenfels, Hans Michael ^e   Philipp, Sandra ^f   Reich, Kristian ^g   Rosenbach, Thomas ^h   Schlaeger, Martin ⁱ   Sebastian, Michael ⁱ   Sterry, Wolfram ^f   Streit, Volker ^j   Weisenseel, Peter ^k   Rzany, Berthold ^l  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Deutscher Psoriasis Bund EV   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Klinikum Hanau   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h Niedergelassener Dermatologe   (Germany)

ⁱ Niedergelassener Dermatologe   (Germany)

^j Niedergelassener Dermatologe   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l NONE

more..

Author keywords

Efalizumab; Guidelines; Psoriasis; Raptiva; Treatment

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; INFLIXIMAB;

CONSENSUS; DISEASE COURSE; DRUG MARKETING; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS VULGARIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT SURVEY; VALIDITY;

EID: 74849126859     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07312.x     Document Type: Short Survey

References (5)

1. Nast A et al. S3-Guidelines for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges 2007 5: Suppl 3: 1 119.
2. http://www.emea.europa.eu/humandocs/Humans/EPAR/raptiva/raptiva.htm
3. Prinz JC. EMEA setzt die Zulassung von Raptiva für die Therapie der Psoriasis aus. Hautarzt 2009 60 (4 345 346.
4. ® (Efalizumab). J Dtsch Dermatol Ges. 2009 7 (4 291 292. DOI
5. Menter A et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol. 2007 46: 637 648.